

Catherine Sermet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12011288/publications.pdf>

Version: 2024-02-01

22
papers

1,491
citations

394286

19
h-index

677027

22
g-index

22
all docs

22
docs citations

22
times ranked

1310
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. <i>BMC Health Services Research</i> , 2010, 10, 153.	0.9	201
2	Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 707-722.	0.7	131
3	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 77-94.	1.3	108
4	Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. <i>Frontiers in Pharmacology</i> , 2014, 5, 106.	1.6	107
5	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , 2018, 6, 328.	1.3	102
6	Ongoing pharmaceutical reforms in France. <i>Applied Health Economics and Health Policy</i> , 2010, 8, 7-24.	1.0	97
7	Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications. <i>Frontiers in Pharmacology</i> , 2010, 1, 141.	1.6	90
8	Personalizing health care: feasibility and future implications. <i>BMC Medicine</i> , 2013, 11, 179.	2.3	81
9	Use of Generics – A Critical Cost Containment Measure for All Healthcare Professionals in Europe?. <i>Pharmaceuticals</i> , 2010, 3, 2470-2494.	1.7	76
10	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. <i>Frontiers in Pharmacology</i> , 2013, 4, 39.	1.6	75
11	Trends in Antimicrobial Drug Use in the Community – France, 1981 – 1992. <i>Journal of Infectious Diseases</i> , 1998, 177, 492-497.	1.9	73
12	Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review. <i>Pharmacoeconomics</i> , 2015, 33, 905-924.	1.7	72
13	Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. <i>Frontiers in Pharmacology</i> , 2016, 7, 305.	1.6	48
14	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. <i>Frontiers in Pharmacology</i> , 2014, 5, 109.	1.6	44
15	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. <i>Frontiers in Pharmacology</i> , 2017, 8, 497.	1.6	34
16	European payer initiatives to reduce prescribing costs through use of generics. <i>GaBI Journal</i> , 2012, 1, 22-27.	0.4	32
17	InÃ©galitÃ©s de santÃ© liÃ©es Ã© l'immigration en France. <i>Revue Economique</i> , 2009, Vol. 60, 385-411.	0.1	28
18	No significant decrease in antibiotic use from 1992 to 2000, in the French community. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 524-528.	1.3	27

#	ARTICLE	IF	CITATIONS
19	Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. <i>Frontiers in Pharmacology</i> , 2016, 7, 197.	1.6	26
20	La morbidite dans les menages originaires du Maghreb. Sur la base de l'enquete Sante de l'Insee, 1991-1992. <i>Population</i> , 1998, 53, 1155.	0.1	17
21	Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: A time-series analysis for France 1998-2010. <i>Health Policy</i> , 2011, 102, 159-169.	1.4	11
22	Multilevel Analysis of the Influence of Patients' and General Practitioners' Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 205-218.	1.0	11